Logo

Alnylam Looks to Sell $450M in Common Stock

Jan 20, 2015 | staff reporter
Premium

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it is planning to sell $450 million of its common stock in a public offering.

The company said that it intends to use the proceeds of the offering for general corporate purposes including the continued advancement of its pipeline of RNAi therapeutics, as well as for working capital and general and administrative expenses.

All of the shares in the offering are being sold by Alnylam.

Filed under

Business News
Gene Editing, Gene Silencing, & CRISPR
stock offering
Alnylam
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.